Related Experiment Video
Updated: Feb 5, 2026
07:49
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
2.0K
[InterAtrial Shunt Device in diastolic heart failure]
1Herzzentrum, Klinik für Kardiologie und Pneumologie, Universitätsmedizin Göttingen, Georg-August-Universität Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Deutschland. hasenfus@med.uni-goettingen.de.
Der Internist
|September 9, 2018
Summary
Interatrial shunts can reduce left atrial pressure in diastolic heart failure patients with pulmonary venous hypertension. Devices like the IASD® show sustained hemodynamic improvement, increasing physical capacity and quality of life.
Area of Science:
- Cardiology
- Medical Devices
- Heart Failure Research
Background:
- Increased left atrial (LA) pressure is a hallmark of heart failure, particularly diastolic heart failure (HFpEF).
- Elevated LA pressure leads to pulmonary venous hypertension (PVH) and impacts symptoms and mortality in HFpEF.
- Interarterial shunts are explored as a treatment to reduce LA pressure in HFpEF with PVH.
Purpose of the Study:
- To evaluate the efficacy and safety of interarterial shunt devices for managing diastolic heart failure.
- To compare the outcomes of the InterAtrial Shunt Device (IASD®) and the V-Wave device.
- To assess the impact of these devices on hemodynamic parameters, physical performance, and quality of life.
Main Methods:
- Review of published data on the InterAtrial Shunt Device (IASD®) and V-Wave device implantation.
- Analysis of hemodynamic and clinical data from patients treated with these devices.
- Assessment of device safety, including complications like paradoxical embolism.
Main Results:
- Both IASD® and V-Wave devices demonstrated sustained hemodynamic improvement in patients.
- No paradoxical embolisms were observed with the IASD®.
- Patients experienced increased physical performance capacity and improved quality of life.
Conclusions:
- Interarterial shunt devices offer a promising therapeutic option for selected HFpEF patients with PVH.
- The IASD® shows potential for broad applicability, with ongoing investigations.
- Clinical use of IASD® in highly symptomatic patients with diastolic heart failure and PVH is established.
Keywords:
Embolism, paradoxicalHeart failure, diastolic, symptomaticHemodynamicsPatient safetyPulmonary wedge pressureMore Related Videos
09:23Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension
Published on: February 11, 2017
17.5K
09:20Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
7.1K
Related Concept Videos
01:29Heart Failure II: Pathophysiology
952
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
952
01:17Pathophysiology of Heart Failure
3.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.8K
01:27Heart Failure I: Introduction
903
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
903
01:22Heart Failure VI: Adjunct Therapies
348
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
348
01:22Heart Failure Drugs: Diuretics
983
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
983
01:30Heart Failure V: Medical Management
330
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
330